Research Article| Volume 12, ISSUE 2, P201-216, June 1992

Monoclonal Antibodies in Cancer Immunotherapy

  • Ralph A. Reisfeld
    Address reprint requests to: Ralph A. Reisfeld, PhD, Division of Tumor Cell Biology, Department of Immunology, IMM13, The Scripps Research Institute, 10666 N. Torrey Pines Road, La Jolla, CA 92037
    From the Division of Tumor Cell Biology, Department of Immunology, The Scripps Research Institute, La Jolla, California
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.
      This article delineates the current status of monoclonal antibodies in cancer immunotherapy. Emphasis is placed on different mechanisms of action by which monoclonal antibodies directed against antigens associated with human melanoma and neuroblastoma may influence the development of novel immunotherapy modalities for cancer. This discussion includes a listing of what is expected of these monoclonal antibodies and a description of some of the problems that must be resolved before these expectations can be realized.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Barker E.
        • Mueller B.M.
        • Handgretinger R.
        • et al.
        Effect of a chimeric antiganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells.
        Cancer Res. 1991; 51: 144
        • Cheung N.-K.V.
        • Lazarus H.
        • Miraldi F.D.
        • et al.
        Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma.
        J Clin Oncol. 1987; 5: 1430
        • Clark M.
        • Gilliland L.
        • Waldmann H.
        Hybrid antibodies for therapy.
        Prog Allergy. 1988; 45: 31
        • Cornil I.
        • Man S.
        • Fernandez B.
        • et al.
        Enhanced tumorigenicity, melanogenesis, and metastases of a human malignant melanoma after subdermal implantation in nude mice.
        Journal of the National Cancer Institute. 1989; 81: 938
        • DeNardo S.J.
        • DeNardo G.L.
        • O’Grady L.F.
        Radioimmunotherapy of patients with B-cell lymphoma using 1-131 LYM-1 mAb.
        J Nucl Med. 1986; 27: 903
        • Dippold W.G.
        • Bernhard H.
        • Dienes H.P.
        • et al.
        Treatment of patients with malignant melanoma by monoclonal ganglioside antibodies.
        Eur J Cancer Clin Oncol. 1988; 24 (suppl): S65
        • Dorai H.
        • Mueller B.M.
        • Reisfeld R.A.
        • et al.
        Aglycosylated chimeric mouse/human antibody retains some effector functions.
        Hybridoma. 1991; 10: 211
        • Douillard J.Y.
        • Lehur P.A.
        • Vignoud J.
        • et al.
        Monoclonal antibodies specific immunotherapy of gastrointestinal tumor.
        Hybridoma. 1986; 5 (suppl 1): S139
        • Elder D.E.
        • Rodeck U.
        • Thurin J.
        • et al.
        Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
        Cancer Res. 1989; 49: 5091
        • Fidler I.J.
        Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis.
        Cancer Metastasis Rev. 1986; 5: 29
        • Gillies S.D.
        • Lo K.M.
        • Wesolowski J.
        High level expression of chimeric antibodies using adopted cDNA variable region cassettes.
        J Immunol Methods. 1989; 125: 191
        • Gillies S.D.
        • Wesolowski J.S.
        Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities.
        Human Antibodies and Hybridomas. 1990; 1: 47
        • Goldenberg D.M.
        Targeting of cancer with radiolabeled antibodies.
        Arch Pathol Lab Med. 1988; 112: 580
        • Goldenberg D.M.
        • Sharkey R.M.
        • Goldenberg H.
        • et al.
        Monoclonal antibody therapy of cancer.
        NJ Med. 1990; 87: 913
        • Gould B.J.
        • Borowitz M.J.
        • Groves E.S.
        • et al.
        Phase I study of an anti-breast cancer immunotoxin by continuous infusion: Report of a targeted toxic effect not predicted by animal studies.
        Journal of the National Cancer Institute. 1989; 81: 775
        • Hersey P.
        • McDonald M.
        • Bums C.
        • et al.
        Enhancement of cytotoxic and proliferative responses of lymphocytes from melanoma patients by incubation with monoclonal antibodies, organs, and ganglioside GD3.
        Cancer Immunol Immunother. 1987; 24: 144
        • Hersey P.
        • Jamal O.
        Expression of gangliosides GD3 and GD2 on lymphocytes in tissue sections of melanoma.
        Pathology. 1989; 21: 51
        • Houghton A.N.
        • Mintzer D.
        • Cordon-Cardo C.
        • et al.
        Mouse monoclonal IgG3 antibody detecting GD3 ganglioside-A phase I trial in patients with malignant melanoma.
        Proc Natl Acad Sci USA. 1985; 82: 1242
        • Iliopoulos D.
        • Ernst C.
        • Steplewski Z.
        • et al.
        Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides.
        Journal of the National Cancer Institute. 1989; 81: 440
        • Ishikawa M.
        • Fernandez B.
        • Kerbel R.S.
        Highly pigmented human melanoma variant which metastasizes widely in nude mice, including to skin and brain.
        Cancer Res. 1988; 48: 4897
        • Janson C.H.
        • Tehrani M.
        • Wigzell H.
        • et al.
        Rational use of biological response modifiers in hematological malignancies: A review of treatment with interferon, cytotoxic cells and antibodies.
        Leukemia Res. 1989; 13: 1039
        • Jung G.
        • Ledbetter J.A.
        • Müller-Eberhard H.J.
        Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates.
        Proc Natl Sci USA. 1987; 84: 4611
        • Köhler G.
        • Milstein C.
        Continuous cultures of fused cells secreting antibody of predefined specificity.
        Nature. 1975; 256: 495
        • Koprowski H.
        • Herlyn M.
        • Balaban G.
        • et al.
        Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma.
        Somatic Cell Mol Genet. 1985; 11: 297
        • Lanzavecchia A.
        • Scheidegger D.
        The use of hybrid hybridomas to target human cytotoxic T lymphocytes.
        Eur J Immunol. 1987; 17: 105
        • Larson S.M.
        • Brown J.P.
        • Wright P.W.
        • et al.
        Imaging of melanoma with 1-131 labeled monoclonal antibodies.
        J Nucl Med. 1983; 24: 123
        • Larson S.M.
        Lymphoma, melanoma, colon cancer: Diagnosis and treatment with radiolabeled monoclonal antibodies.
        Radiology. 1987; 165: 297
        • Ledbetter J.A.
        • Martin P.J.
        • Spooner C.E.
        • et al.
        Antibodies to Tp67 and Tp44 augment and sustain proliferative responses to activated T cells.
        J Immunol. 1985; 135: 2331
        • Masui H.
        • Kawamoto T.
        • Sato J.D.
        • et al.
        Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies.
        Cancer Res. 1984; 44: 1002
        • Mellstedt H.
        • Frodin J.-E.
        • Masucci G.
        Clinical status of monoclonal antibodies in the treatment of colorectal carcinoma.
        Oncology. 1989; 3: 25
        • Milstein C.
        • Cuello A.C.
        Hybrid hybridomas and their use in immunohistochemistry.
        Nature. 1983; 305: 537
        • Möller S.A.
        • Reisfeld R.A.
        Bispecific monoclonal antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes.
        Cancer Immunol Immunother. 1991; 33: 210
        • Morrison S.L.
        Transfectomas provide novel chimeric antibodies.
        Science. 1985; 229: 1202
        • Mueller B.M.
        • Romerdahl C.A.
        • Reisfeld R.A.
        Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.
        J Immunol. 1990; 144: 1382
        • Mueller B.M.
        • Reisfeld R.A.
        • Gillies S.D.
        Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2.
        Proc Natl Acad Sci USA. 1990; 87: 5702
        • Mueller B.M.
        • Wrasidlo W.A.
        • Reisfeld R.A.
        Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers.
        Bioconjugate Chem. 1990; 1: 325
        • Mueller B.M.
        • Reisfeld R.A.
        • Silveira M.H.
        • et al.
        Pre-clinical therapy of human melanoma with morpholino-doxorubicin conjugated to a monoclonal antibody directed against an integrin on melanoma cells.
        Antibody Immunoconjugates Radiopharm. 1991; 4: 99
        • Mueller B.M.
        • Romerdahl C.A.
        • Reisfeld R.A.
        Suppression of spontaneous melanoma metastasis in Scid mice with an antibody to the epidermal growth factor receptor.
        Cancer Res. 1991; 51: 2193
        • Mujoo K.
        • Cheresh D.A.
        • Reisfeld R.A.
        Disialoganglioside GD2 on human neuroblastoma: Target antigen for monoclonal antibody mediated cytolysis and suppression of tumor growth.
        Cancer Res. 1986; 47: 1098
        • Neuberger M.S.
        • Williams G.T.
        • Fox R.O.
        Recombinant antibodies possessing novel effector functions.
        Nature. 1984; 312: 604
        • Order S.E.
        Systemic radiotherapy—the new frontier.
        Int J Radiat Oncol Biol Phys. 1990; 18: 981
        • Perez M.S.
        • Walker L.E.
        Isolation and characterization of a cDNA encoding the KS1/4 epithelial carcinoma marker.
        J Immunol. 1989; 142: 3662
        • Perez P.
        • Hoffman R.W.
        • Shaw S.
        • et al.
        Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody.
        Nature. 1985; 316: 354
        • Real F.X.
        • Rettig W.J.
        • Chesa P.G.
        • et al.
        Expression of epidermal growth factor receptor in human cultured cells and tissues: Relationship to cell lineage and stage of differentiation.
        Cancer Res. 1986; 46: 4726
        • Reisfeld R.A.
        • Cheresh D.A.
        Human tumor antigens.
        in: Dixon F.J. Advances in Immunology. Academic Press, New York1987: 323
        • Rodeck U.
        • Herlyn M.
        • Menssen H.D.
        • et al.
        Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors.
        Int J Cancer. 1987; 40: 687
        • Rodeck U.
        • Herlyn M.
        • Herlyn D.
        • et al.
        Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: Immunologically mediated and effector cell-independent effects.
        Cancer Res. 1987; 47: 3692
        • Schneck D.
        • Butler F.
        • Dugan W.
        • et al.
        Phase I studies with a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinoma.
        Antibody Immunoconjugates Radiopharm. 1989; 2: 93
      1. Schrappe M, Bumol TF, Apelgren LD, et al: Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of desacetylvinblastine-hydrazide and monoclonal antibody 9.2.27. Submitted for publication, 1991

        • Scott C.F.
        • Bolender S.
        • McIntyre G.D.
        • et al.
        Activation of human cytolytic cells through CD2/T11. Comparison of the requirements for the induction and direction of lysis of tumor targets by T cells and NK cells.
        J Immunol. 1989; 142: 4105
        • Sears H.G.
        • Atkinson B.
        • Herlyn D.
        • et al.
        The use of monoclonal antibody in a phase I clinical trial of human gastrointestinal tumor.
        Lancet. 1982; 1: 762
        • Segal D.M.
        • Wunderlich J.R.
        Targeting of cytotoxic cells with heterocrosslinked antibodies.
        Cancer Invest. 1988; 6: 83
        • Segal D.M.
        • Garrido M.A.
        • Perez P.
        • et al.
        Targeted cytotoxic cells as a novel form of cancer immunotherapy.
        Mol Immunol. 1988; 25: 1099
        • Staerz U.D.
        • Kanagawa O.
        • Bevan M.J.
        Hybrid antibodies can target sites for attack by T cells.
        Nature. 1985; 314: 628
        • Vadhan-Raj S.
        • Cordon-Cardo C.
        • Carswell E.
        • et al.
        Phase I trial of mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: Induction of inflammatory responses at tumor sites.
        J Clin Oncol. 1988; 6: 1636
        • Vaughan A.T.M.
        • Anderson P.
        • Dykes P.W.
        • et al.
        Limitations to the killing of tumors using radiolabelled antibodies.
        Br J Radiol. 1987; 60: 567
        • Vitetta E.S.
        • Fulton R.J.
        • May R.D.
        • et al.
        Redesigning nature’s poisons to create anti-tumor reagents.
        Science. 1987; 238: 1098
        • Welte K.
        • Miller G.
        • Chapman P.B.
        • et al.
        Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside.
        J Immunol. 1987; 139: 1763